Key result
PCSK9 inhibitors achieve ≥50% LDL-C reduction in ~80% of patients, but stricter targets lag.
Why the study?
There is limited real-world evidence on the attainment of guideline LDL-C targets using PCSK9 inhibitors in patients with ASCVD and/or familial hypercholesterolaemia.
Observational (n=55)
No
Stricter LDL-C targets are often unmet with PCSK9 inhibitors; leaves open optimal intensification strategies for high-risk patients.
Background: Trial evidence for lower LDL cholesterol (LDL-C) treatment targets for cardiovascular benefit were incorporated into recent European Society of Cardiology/European Atherosclerosis Society and NICE guidelines. Treatment targets are LDL-C <1.4mmol/L, LDL-C <1.8mmol/L and ≥50% LDL-C reduction for atherosclerotic cardiovascular disease (ASCVD) and/or Familial Hypercholesterolaemia (FH). There is limited real-world evidence of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9is), with enhanced LDL-C lowering, achieving these targets. Aims: To assess attainment of guideline LDL-C targets using PCSK9is ± oral lipid-lowering therapies (LLT) in ASCVD and/or FH. Methods: Clinic-based audit using retrospective case-note review of adults prescribed PCSK9is. Anonymised data were collected before and after PCSK9i initiation. Standards were attainment of LDL-C <1.8mmol/L, LDL-C <1.4mmol/L and ≥50% LDL-C reduction. Results: Fifty-five patients (mean age 60.8 years) receiving PCSK9is (35% monotherapy; median treatment duration 1.5 years) were identified (ASCVD, n=50; FH, n=18). Target attainment was 80% for ≥50% LDL-C reduction, 46% for LDL-C <1.8mmol/L and 24% for LDL-C <1.4mmol/L. Greater attainment of these targets occurred with ≥2 additional LLTs versus one additional LLT or PCSK9i monotherapy. Conclusion: Most ASCVD and/or FH patients achieved ≥50% LDL-C reductions with PCSK9is. Fewer achieved LDL-C <1.8mmol/L and <1.4mmol/L targets. PCSK9is in combination with other LLT achieved targets more often compared to PCSK9i monotherapy. Achievement of recommended lipid targets may require greater use of PCSK9i combination therapies.
No takes yet. Share an insight, caveat, or question.
Theodoraki et al. (2022) conducted an observational in Atherosclerotic cardiovascular disease (ASCVD) and/or Familial Hypercholesterolaemia (FH) (n=55). PCSK9 inhibitors was evaluated on Attainment of ≥50% LDL-C reduction from baseline. PCSK9 inhibitor therapy achieved a ≥50% LDL-C reduction in 79.6% of patients, while stricter LDL-C targets of <1.8 mmol/L and <1.4 mmol/L were achieved by only 46.3% and 24.1% of patients, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: